Patents Assigned to Bayer Intellectual Property GmbH
  • Publication number: 20190010150
    Abstract: The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory.
    Type: Application
    Filed: January 30, 2018
    Publication date: January 10, 2019
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Joachim LUITHLE, Frank-Gerhard BÖß, Christina ERB, Katrin SCHNIZLER, Timo FLESSNER, Marja van KAMPEN, Christoph METHFESSEL
  • Publication number: 20180258181
    Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the invention also can be used in the diagnostics field, as well as for further investigating the role of mesothelin in the progression of disorders associated with cancer. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Application
    Filed: March 5, 2018
    Publication date: September 13, 2018
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Antje KAHNERT, David LIGHT, Doug SCHNEIDER, Renate PARRY, Noboru SATOZAWA, Tara HEITNER, Stefan STEIDL, Ulrike SCHUBERT
  • Patent number: 10035818
    Abstract: The invention relates to novel polyethylene glycol (PEG) based prodrug of Adrenomedullin, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for producing medicaments for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: July 31, 2018
    Assignees: Bayer Pharma Aktiengesellschaft, Bayer Intellectual Property GmbH
    Inventors: Ingo Flamme, Johannes Köbberling, Hans-Georg Lerchen, Nils Griebenow, Rudolf Schohe-Loop, Sven Wittrock, Maria Köllnberger, Frank Wunder, Gorden Redlich, Andreas Knorr, Julie Marley, Iain Pritchard
  • Publication number: 20180201690
    Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, e.g. solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.
    Type: Application
    Filed: March 16, 2018
    Publication date: July 19, 2018
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Antje Kahnert, Kerstin Unterschemmann, Iring Heisler, Charlotte Christine Kopitz, Joachim Schuhmacher
  • Publication number: 20180153957
    Abstract: The invention relates to preparations comprising amorphous emodepside in a polyvinylpyrrolidone matrix, pharmaceuticals comprising such preparations, and their use against endoparasites in animals or humans.
    Type: Application
    Filed: November 3, 2017
    Publication date: June 7, 2018
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Venkata-Rangarao KANIKANTI, Petra LANGE, Hans-Juergen HAMANN, Peter KLEINEBUDDE
  • Patent number: 9969717
    Abstract: The present invention relates to a process for preparing substituted anthranilic acid derivatives of the formula (I) in which R1, R2, R3 and R4 are each as defined in the description, by conversion of compounds of the general formula (IV) in the presence of a palladium catalyst and carbon monoxide. The present invention likewise relates to compounds of the general formula (IV).
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: May 15, 2018
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Thomas Himmler, Sergii Pazenok, Frank Volz, Norbert Lui
  • Patent number: 9962389
    Abstract: The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: May 8, 2018
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ulrich Lücking, Rolf Bohlmann, Arne Scholz, Gerhard Siemeister, Mark Jean Gnoth, Ulf Bömer, Dirk Kosemund, Philip Lienau, Gerd Rühter, Carsten Schultz-Fademrecht
  • Patent number: 9920138
    Abstract: The present invention relates to alternan-carboxylic acid esters, to processes for the preparation of alternan-carboxylic acid esters, and to compositions comprising alternan-carboxylic acid esters and to the use of alternan-carboxylic acid esters. The invention relates to alternan-carboxylic acid esters which are emulsifiers.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: March 20, 2018
    Assignee: Bayer Intellectual Property GMBH
    Inventors: Claus Frohberg, Waltraud Vorwerg, Sylvia Radosta
  • Patent number: 9902727
    Abstract: This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: February 27, 2018
    Assignee: Bayer Intellectual Property GmbH
    Inventors: William Scott, Ningshu Liu, Manfred Möwes, Andrea Hägebarth, Ursula Mönning, Ulf Bömer
  • Publication number: 20170327589
    Abstract: The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and/or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and/or diagnose and/or monitor cancers, solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.
    Type: Application
    Filed: July 21, 2017
    Publication date: November 16, 2017
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Antje KAHNERT, Kerstin UNTERSCHEMMANN, Iring HEISLER, Charlotte KOPITZ, Joachim SCHUMACHER
  • Patent number: 9777063
    Abstract: The present invention is directed to the neutralizing prolactin receptor antibody Mat3, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation and for the treatment and prevention of antiestrogen-resistant breast cancer. The antibody of the invention blocks prolactin receptor-mediated signalling.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: October 3, 2017
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Christoph Freiberg, Christiane Otto, Lars Linden, Axel Harrenga, Mark Trautwein, Simone Greven, Andreas Wilmen
  • Patent number: 9763451
    Abstract: The invention relates to a method for improving the utilization of the production potential of a genetically modified plant where the plant is treated with an effective amount of at least one compound of the formula (I) in which R1 to R3, X, L, n and Y have the meanings given in the description.
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: September 19, 2017
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Peter Jeschke, Wolfram Andersch, Heike Hungenberg
  • Publication number: 20170260198
    Abstract: Compounds of formula (1) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: February 21, 2017
    Publication date: September 14, 2017
    Applicants: Bayer Intellectual Property GmbH, Bayer Pharma Aktiengesellschaft
    Inventors: Marion HITCHCOCK, Anne MENGEL, Vera PÜTTER, Gerhard SIEMEISTER, Antje Margret WENGNER, Hans BRIEM, Knut EIS, Volker SCHULZE, Amaury Ernesto FERNANDEZ-MONTALVAN, Stefan PRECHTL, Simon HOLTON, Jörg FANGHÄNEL, Philip LIENAU, Cornelia PREUSSE, Mark Jean GNOTH
  • Patent number: 9751871
    Abstract: Bis(difluoromethyl)pyrazole derivatives of the formula (I) in which the symbols R1, X and G are each as defined in the description, and agrochemically active salts, metal complexes and N-oxides thereof, and use thereof for controlling phytopathogenic harmful fungi, and also processes for preparing compounds of the formula (I).
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: September 5, 2017
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Pierre Cristau, Sebastian Hoffmann, Joachim Kluth, Tomoki Tsuchiya, Pierre Wasnaire, Jurgen Benting, Daniela Portz, Ulrike Wachendorff-Neumann, Stefan Hillebrand
  • Patent number: 9724497
    Abstract: Various methods for optimizing coating of medical devices, such as balloon catheters are disclosed. One method configures catheter balloon folds based on balloon diameter and volume. Other methods include using a specifically-sized protective sheath, using a vacuum, using pressure, pulling the balloon through a coating solution, using at least one spacer or a wick between at least one fold for metering a therapeutic coating into the folds of the balloon, placing an intermediate layer between the balloon and the therapeutic coating, placing a soluble film having a therapeutic agent around the catheter balloon or inside the folds, and any combination thereof. Balloon catheters and catheter balloons having a specific folding configuration, a specifically-sized protective sheath, an intermediate layer, or a soluble film are also disclosed.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: August 8, 2017
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Benjamin T. Ewing, Gregory G. Brucker, Scott A. Bednar, John R. Periard, Ashok A. Sharma, Steven D. Savage, Arthur E. Uber, Brian P. Dickerson
  • Publication number: 20170217949
    Abstract: The present invention relates to 4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group of general formula (I) or (Ia) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I) or (Ia).
    Type: Application
    Filed: April 14, 2017
    Publication date: August 3, 2017
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Ulrich LÜCKING, Rolf BOHLMANN, Arne SCHOLZ, Gerhard SIEMEISTER, Mark Jean GNOTH, Ulf BÖMER, Dirk KOSEMUND, Philip LIENAU, Gerd RÜHTER, Carsten SCHULTZ-FADEMRECHT
  • Patent number: 9714242
    Abstract: The invention relates to novel benzothiophene-, benzofuran-, and indole ureas and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning, and/or memory.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: July 25, 2017
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Timo Fleβner, Frank-Gerhard Böβ, Christina Erb, Frank-Thorsten Hafner, Katrin Schnizler, Dieter Lang, Joachim Luithle, Marja Van Kampen, Franz-Josef Van Der Staay
  • Patent number: 9699956
    Abstract: A seeding machine (1) and method of use, for introducing seed material into a soil (11), with a first ploughing device for drawing at least one furrow into the soil and a filling device for closing the first furrow. A dust separator (5) separates air during the seeding process into an air component (13) and a dust component (7). A line from the dust separator delivers the dust component separated from the air component into the soil.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: July 11, 2017
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Adrian Christopher Arnold, Lubos Vrbka, Charles Andrew Chapple
  • Publication number: 20170182118
    Abstract: The invention relates to preparations comprising amorphous emodepside in a polyvinylpyrrolidone matrix, pharmaceuticals comprising such preparations, and their use against endoparasites in animals or humans.
    Type: Application
    Filed: January 4, 2017
    Publication date: June 29, 2017
    Applicant: Bayer Intellectual Property GmbH
    Inventors: Kanikanti VENKATA-RANGARAO, Petra LANGE, Hans-Jürgen HAMANN, Peter KLEINEBUDDE
  • Patent number: RE46856
    Abstract: This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyperproliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: May 22, 2018
    Assignee: Bayer Intellectual Property GMBH
    Inventors: Martin Hentemann, Jill Wood, William Scott, Martin Michels, Ann-Marie Campbell, Ann-Marie Bullion, Bruce R. Rowley, Aniko Redman